These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
186 related articles for article (PubMed ID: 38950729)
1. Recent advances in the molecular design and applications of viral RNA-targeting antiviral modalities. Dai J; Jiang X; da Silva-Júnior EF; Du S; Liu X; Zhan P Drug Discov Today; 2024 Aug; 29(8):104074. PubMed ID: 38950729 [TBL] [Abstract][Full Text] [Related]
2. Application of modified antisense oligonucleotides and siRNAs as antiviral drugs. Wagner A; Bock CT; Fechner H; Kurreck J Future Med Chem; 2015; 7(13):1637-42. PubMed ID: 26381598 [No Abstract] [Full Text] [Related]
9. Newly Emerging Strategies in Antiviral Drug Discovery: Dedicated to Prof. Dr. Erik De Clercq on Occasion of His 80th Anniversary. Xu S; Ding D; Zhang X; Sun L; Kang D; Huang B; Liu X; Zhan P Molecules; 2022 Jan; 27(3):. PubMed ID: 35164129 [TBL] [Abstract][Full Text] [Related]
10. RNA as a target for developing antivirals. McKnight KL; Heinz BA Antivir Chem Chemother; 2003 Mar; 14(2):61-73. PubMed ID: 12856917 [TBL] [Abstract][Full Text] [Related]
11. RNA Therapeutics in Oncology: Advances, Challenges, and Future Directions. MacLeod AR; Crooke ST J Clin Pharmacol; 2017 Oct; 57 Suppl 10():S43-S59. PubMed ID: 28921648 [TBL] [Abstract][Full Text] [Related]
12. Targeting Highly Structured RNA by Cooperative Action of siRNAs and Helper Antisense Oligomers in Living Cells. Dutkiewicz M; Ojdowska A; Kuczynski J; Lindig V; Zeichhardt H; Kurreck J; Ciesiołka J PLoS One; 2015; 10(8):e0136395. PubMed ID: 26308932 [TBL] [Abstract][Full Text] [Related]
13. The program of antiviral agents inhibits virus infection. Ding YZ; Lv JL; Zhang ZW; Ma XY; Zhang J; Zhang YG Arch Microbiol; 2018 Aug; 200(6):841-846. PubMed ID: 29846759 [TBL] [Abstract][Full Text] [Related]
14. Efficient Inhibition of SARS-CoV-2 Using Chimeric Antisense Oligonucleotides through RNase L Activation*. Su X; Ma W; Feng D; Cheng B; Wang Q; Guo Z; Zhou D; Tang X Angew Chem Int Ed Engl; 2021 Sep; 60(40):21662-21667. PubMed ID: 34278671 [TBL] [Abstract][Full Text] [Related]
16. Oligonucleotides as antivirals: dream or realistic perspective? Van Aerschot A Antiviral Res; 2006 Sep; 71(2-3):307-16. PubMed ID: 16621039 [TBL] [Abstract][Full Text] [Related]
17. Antiviral Efficacy of RNase H-Dependent Gapmer Antisense Oligonucleotides against Japanese Encephalitis Virus. Okamoto S; Echigoya Y; Tago A; Segawa T; Sato Y; Itou T Int J Mol Sci; 2023 Oct; 24(19):. PubMed ID: 37834294 [TBL] [Abstract][Full Text] [Related]
18. Oligonucleotide-based therapeutic options against hepatitis C virus infection. Trepanier JB; Tanner JE; Alfieri C Antivir Ther; 2006; 11(3):273-87. PubMed ID: 16759043 [TBL] [Abstract][Full Text] [Related]
19. Broad-spectrum and virus-specific nucleic acid-based antivirals against influenza. Wong JP; Christopher ME; Salazar AM; Sun LQ; Viswanathan S; Wang M; Saravolac EG; Cairns MJ Front Biosci (Schol Ed); 2010 Jan; 2(2):791-800. PubMed ID: 20036985 [TBL] [Abstract][Full Text] [Related]
20. Antitumoral RNA-targeted oligonucleotide therapeutics: The third pillar after small molecule inhibitors and antibodies. Taniguchi H; Suzuki Y; Imai K; Adachi Y Cancer Sci; 2022 Sep; 113(9):2952-2961. PubMed ID: 35701833 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]